Rubicon Research Ltd. share price target

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research is a fast-growing research and development-driven pharmaceutical manufacturing company with a focus on regulated markets (particularly the US).

Rubicon is one of the fastest growing Indian pharmaceutical companies focusing completely on the US market which contributed ~99% of the FY25 revenues. It has a pipeline of 17 products under review with the USFDA and...

Company is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States. Based on the peer set (of seven listed Indian companies assessed by F&S, and Company), company is the only Indian pharmaceutical player with a complete focus on regulated markets. Between Fiscals 2023 and 2025, company was...

IPO Note

Rubicon Research Ltd (RRL) is an innovation-driven and R&D focused pharmaceutical formulations company with an increasing portfolio of specialty products and drug-device combination products concentrated in USA (~99.6% of 1QFY26 revenue). As of Jun'25, its product portfolio included 72 active Abbreviated New Drug Applications (ANDAs), 9 active New Drug Applications (NDAs) and 1 Over-the-Counter (OTC) monography listed with the United States Food & Drug Administration (USFDA), which includes 16 specialty products. During FY25, RRL held a market share of...